{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T01:14:07Z","timestamp":1778721247423,"version":"3.51.4"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100014054","name":"Drugs for Neglected Diseases initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.ejmech.2020.112914","type":"journal-article","created":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T11:16:28Z","timestamp":1602328588000},"page":"112914","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Heteroaryl ether analogues of an antileishmanial 7-substituted 2-nitroimidazooxazine lead afford attenuated hERG risk: In\u00a0vitro and in\u00a0vivo appraisal"],"prefix":"10.1016","volume":"209","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2593-8559","authenticated-orcid":false,"given":"Andrew M.","family":"Thompson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick D.","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0022-2001","authenticated-orcid":false,"given":"Andrew J.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Yardley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Maes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suman","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6862-4723","authenticated-orcid":false,"given":"Delphine","family":"Launay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6354-3059","authenticated-orcid":false,"given":"Stephanie","family":"Braillard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Chatelain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baojie","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8698-0243","authenticated-orcid":false,"given":"Scott G.","family":"Franzblau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenkun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2631-6818","authenticated-orcid":false,"given":"Christopher B.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7997-1843","authenticated-orcid":false,"given":"William A.","family":"Denny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2020.112914_bib1","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/S0140-6736(09)60233-6","article-title":"Rescuing the bottom billion through control of neglected tropical diseases","volume":"373","author":"Hotez","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2020.112914_bib2","author":"World Health Organization"},{"key":"10.1016\/j.ejmech.2020.112914_bib3","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2147\/CLEP.S44267","article-title":"Epidemiology of visceral leishmaniasis","volume":"6","author":"Ready","year":"2014","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.ejmech.2020.112914_bib4","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.transci.2017.09.007","article-title":"Global status of visceral leishmanial infection among blood donors: a systematic review and meta-analysis","volume":"56","author":"Asfaram","year":"2017","journal-title":"Transfus. Apher. Sci."},{"key":"10.1016\/j.ejmech.2020.112914_bib5","doi-asserted-by":"crossref","DOI":"10.1093\/femspd\/ftz057","article-title":"Impact of sequelae of visceral leishmaniasis and their contribution to ongoing transmission of Leishmania donovani","volume":"77","author":"Duthie","year":"2019","journal-title":"Pathog. Dis."},{"key":"10.1016\/j.ejmech.2020.112914_bib6","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/cid\/ciy891","article-title":"Quantifying the infectiousness of post-kala-azar dermal leishmaniasis toward sand flies","volume":"69","author":"Mondal","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejmech.2020.112914_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185438","article-title":"Field trial of efficacy of the Leish-tec\u00ae vaccine against canine leishmaniasis caused by Leishmania infantum in an endemic area with high transmission rates","volume":"12","author":"Grimaldi","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.ejmech.2020.112914_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005527","article-title":"A\u00a0third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: first-in-human trial of ChAd63-KH","volume":"11","author":"Osman","year":"2017","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ejmech.2020.112914_bib9","doi-asserted-by":"crossref","first-page":"95","DOI":"10.4103\/ijpvm.IJPVM_116_18","article-title":"Leishmania vaccines entered in clinical trials: a review of literature","volume":"10","author":"Moafi","year":"2019","journal-title":"Int. J. Prev. Med."},{"key":"10.1016\/j.ejmech.2020.112914_bib10","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1017\/S0031182017002116","article-title":"Chemotherapeutics of visceral leishmaniasis: present and future developments","volume":"145","author":"Sundar","year":"2018","journal-title":"Parasitology"},{"key":"10.1016\/j.ejmech.2020.112914_bib11","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1017\/S0031182016002523","article-title":"Chemotherapy of leishmaniasis: present challenges","volume":"145","author":"Uliana","year":"2018","journal-title":"Parasitology"},{"key":"10.1016\/j.ejmech.2020.112914_bib12","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1017\/S0031182016002031","article-title":"Evaluating drug resistance in visceral leishmaniasis: the challenges","volume":"145","author":"Hendrickx","year":"2018","journal-title":"Parasitology"},{"key":"10.1016\/j.ejmech.2020.112914_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004880","article-title":"Efficacy and safety of AmBisome in combination with sodium stibogluconate or miltefosine and miltefosine monotherapy for African visceral leishmaniasis: phase II randomized trial","volume":"10","author":"Wasunna","year":"2016","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ejmech.2020.112914_bib14","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1093\/cid\/cix607","article-title":"The risk and predictors of visceral leishmaniasis relapse in human immunodeficiency virus-coinfected patients in Ethiopia: a retrospective cohort study","volume":"65","author":"Abongomera","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejmech.2020.112914_bib15","article-title":"Visceral leishmaniasis and HIV co-infection in Bihar, India: long-term effectiveness and treatment outcomes with liposomal amphotericin B (AmBisome)","volume":"8","author":"Burza","year":"2014","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ejmech.2020.112914_bib16","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.actatropica.2015.12.016","article-title":"Visceral leishmaniasis: revisiting current treatments and approaches for future discoveries","volume":"155","author":"No","year":"2016","journal-title":"Acta Trop."},{"key":"10.1016\/j.ejmech.2020.112914_bib17","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.drudis.2017.06.004","article-title":"Leishmaniasis drug discovery: recent progress and challenges in assay development","volume":"22","author":"Zulfiqar","year":"2017","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2020.112914_bib18","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s40265-019-01207-9","article-title":"Pretomanid: first approval","volume":"79","author":"Keam","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2020.112914_bib19","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1021\/jm501608q","article-title":"Synthesis and structure-activity relationships for extended side chain analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)","volume":"58","author":"Palmer","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112914_bib20","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1021\/acs.jmedchem.7b00034","article-title":"7-Substituted 2-nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: novel antitubercular agents lead to a new preclinical candidate for visceral leishmaniasis","volume":"60","author":"Thompson","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112914_bib21","series-title":"Nitroimidazooxazine and Nitroimidazooxazole Analogues and Their Uses","author":"Thompson","year":"2012"},{"key":"10.1016\/j.ejmech.2020.112914_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005971","article-title":"Activation of bicyclic nitro-drugs by a novel nitroreductase (NTR2) in Leishmania","volume":"12","author":"Wyllie","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ejmech.2020.112914_bib23","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1021\/acs.jmedchem.5b01699","article-title":"Repositioning antitubercular 6-nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for neglected tropical diseases: structure\u2013activity studies on a preclinical candidate for visceral leishmaniasis","volume":"59","author":"Thompson","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112914_bib24","first-page":"393","article-title":"Reducing the risk of drug attrition associated with physicochemical properties","volume":"45","author":"Leeson","year":"2010","journal-title":"Annu. Rep. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112914_bib25","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jddst.2015.05.009","article-title":"Strategies for formulating and delivering poorly water-soluble drugs","volume":"30","author":"Rodriguez-Aller","year":"2015","journal-title":"J.\u00a0Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejmech.2020.112914_bib26","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ejps.2012.07.019","article-title":"Optimizing solubility: kinetic versus thermodynamic solubility temptations and risks","volume":"47","author":"Saal","year":"2012","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.ejmech.2020.112914_bib27","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1039\/C1MD00017A","article-title":"Molecular obesity, potency and other addictions in drug discovery","volume":"2","author":"Hann","year":"2011","journal-title":"Med. Chem. Commun."},{"key":"10.1016\/j.ejmech.2020.112914_bib28","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nrd4683","article-title":"Hit and lead criteria in drug discovery for infectious diseases of the developing world","volume":"14","author":"Katsuno","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2020.112914_bib29","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nrd.2016.85","article-title":"Trends in clinical success rates","volume":"15","author":"Smietana","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2020.112914_bib30","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1021\/acs.jmedchem.7b01581","article-title":"Development of (6R)-2-nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (DNDI-8219): a new lead for visceral leishmaniasis","volume":"61","author":"Thompson","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112914_bib31","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1039\/b807733a","article-title":"First total synthesis of (R,R,R)- and (3R,5S,9R)-bejarol by gold-catalyzed allene cycloisomerization and determination of absolute configuration of the natural product","volume":"6","author":"Sawama","year":"2008","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2020.112914_bib32","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1002\/ejoc.201301627","article-title":"A\u00a0ring-closing enyne metathesis approach to functionalized semicyclic dienes: the total synthesis of (-)-tetrangomycin","author":"Moodie","year":"2014","journal-title":"Eur. J. Org Chem."},{"key":"10.1016\/j.ejmech.2020.112914_bib33","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1021\/jo01311a058","article-title":"The triisopropylsilyl group as a hydroxyl-protecting function","volume":"45","author":"Cunico","year":"1980","journal-title":"J.\u00a0Org. Chem."},{"key":"10.1016\/j.ejmech.2020.112914_bib34","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/jac\/dku422","article-title":"Nitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis","volume":"70","author":"Gupta","year":"2015","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2020.112914_bib35","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1177\/1087057115569155","article-title":"Repurposing of the open access malaria box for kinetoplastid diseases identifies novel active scaffolds against trypanosomatids","volume":"20","author":"Kaiser","year":"2015","journal-title":"J.\u00a0Biomol. Screen."},{"key":"10.1016\/j.ejmech.2020.112914_bib36","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1128\/AAC.49.4.1447-1454.2005","article-title":"In\u00a0vitro and in\u00a0vivo activities of macrolide derivatives against Mycobacterium tuberculosis, Antimicrob","volume":"49","author":"Falzari","year":"2005","journal-title":"Agents Chemother"},{"key":"10.1016\/j.ejmech.2020.112914_bib37","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1128\/AAC.00055-06","article-title":"Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis","volume":"51","author":"Cho","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2020.112914_bib38","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.parint.2016.10.020","article-title":"Imaging visceral leishmaniasis in real time with golden hamster model: monitoring the parasite burden and hamster transcripts to further characterize the immunological responses of the host","volume":"66","author":"Rouault","year":"2017","journal-title":"Parasitol. Int."},{"key":"10.1016\/j.ejmech.2020.112914_bib39","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/bjp.2008.267","article-title":"Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized Guinea-pig model","volume":"154","author":"Yao","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.112914_bib40","doi-asserted-by":"crossref","first-page":"5029","DOI":"10.1021\/jm060379l","article-title":"Medicinal chemistry of hERG optimizations: highlights and hang-ups","volume":"49","author":"Jamieson","year":"2006","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112914_bib41","unstructured":"Drugs for Neglected Diseases initiative, Target product profile for visceral leishmaniasis, Available at, https:\/\/dndi.org\/diseases\/visceral-leishmaniasis\/target-product-profile\/. (Accessed 26 June 2020)."},{"key":"10.1016\/j.ejmech.2020.112914_bib42","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1128\/AAC.00722-13","article-title":"The R enantiomer of the antitubercular drug PA-824 as a potential oral treatment for visceral leishmaniasis","volume":"57","author":"Patterson","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2020.112914_bib43","author":"GlaxoSmithKline"},{"key":"10.1016\/j.ejmech.2020.112914_bib44","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41586-018-0356-z","article-title":"Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis","volume":"560","author":"Wyllie","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2020.112914_bib45","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00048-18","article-title":"Recent development of visceral leishmaniasis treatments: successes, pitfalls, and perspectives","volume":"31","author":"Alves","year":"2018","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ejmech.2020.112914_bib46","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40249-016-0112-2","article-title":"Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective","volume":"5","author":"Singh","year":"2016","journal-title":"Infect. Dis. Poverty"},{"key":"10.1016\/j.ejmech.2020.112914_bib47","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejps.2014.09.006","article-title":"In\u00a0vitro metabolism, disposition, preclinical pharmacokinetics and prediction of human pharmacokinetics of DNDI-VL-2098, a potential oral treatment for visceral leishmaniasis","volume":"65","author":"Mukkavilli","year":"2014","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.ejmech.2020.112914_bib48","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0014-2999(01)01362-0","article-title":"[3H]Dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen","volume":"430","author":"Finlayson","year":"2001","journal-title":"Eur. J. Pharmacol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420308862?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420308862?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:25:21Z","timestamp":1759328721000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523420308862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":48,"alternative-id":["S0223523420308862"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112914","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heteroaryl ether analogues of an antileishmanial 7-substituted 2-nitroimidazooxazine lead afford attenuated hERG risk: In\u00a0vitro and in\u00a0vivo appraisal","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112914","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112914"}}